• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多柔比星诱导慢性髓系白血病细胞获得的多药耐药细胞具有肿瘤起始细胞特性。

Multi-drug-resistant cells enriched from chronic myeloid leukemia cells by Doxorubicin possess tumor-initiating-cell properties.

机构信息

Department of Pharmacology, School of Pharmacy, Fudan University, Shanghai 201203, P.R. China.

出版信息

J Pharmacol Sci. 2013;122(4):299-304. doi: 10.1254/jphs.13025fp. Epub 2013 Aug 1.

DOI:10.1254/jphs.13025fp
PMID:23903006
Abstract

Multiple drug resistance (MDR) occurring during chemotherapy is a major obstacle for treatment of cancers using chemotherapeutic drugs; thus, the mechanisms underlying MDR have attracted intensive attention. Many studies have shown that tumor-initiating cells exhibit a chemotherapeutic tolerance characteristic. However, whether the MDR cells possess tumor-initiating cells properties and its underlying mechanisms remain to be fully elucidated. In this study, we utilized a well-established MDR cell line K562/A02 enriched by doxorubicin from K562 cells to determine if the K562/A02 cells possess tumor-initiating properties and investigated its potential molecular mechanisms. We observed that the expressions of Oct4, Sox2, and Nanog, all of which are well-characterized stem cell markers, in K562/A02 cells were elevated in comparison to parental K562 cells; in addition, we found that K562/A02 cells exhibited more potent in vitro and in vivo tumor-initiating properties, as revealed by sphere assay, self-renewal assay, soft agar assay, and animal studies. Furthermore, our data suggest that snail and twist1, two well known transcriptional factors for the epithelial-mesenchymal transition (EMT) program, may be potentially involved in the acquisition of tumor-initiating properties of K562/A02 cells. Thus, our study demonstrates that MDR K562/A02 cells possess tumor-initiating properties, most likely due to the elevated expressions of snail and twist1.

摘要

多药耐药(MDR)在化疗过程中发生,是使用化疗药物治疗癌症的主要障碍;因此,MDR 的机制引起了广泛关注。许多研究表明,肿瘤起始细胞表现出化疗耐受性特征。然而,MDR 细胞是否具有肿瘤起始细胞特性及其潜在机制仍有待充分阐明。在这项研究中,我们利用阿霉素从 K562 细胞中富集的已建立的 MDR 细胞系 K562/A02,来确定 K562/A02 细胞是否具有肿瘤起始特性,并研究其潜在的分子机制。我们观察到,与亲本 K562 细胞相比,K562/A02 细胞中 Oct4、Sox2 和 Nanog 的表达升高,这三种蛋白均为特征明确的干细胞标志物;此外,我们发现 K562/A02 细胞表现出更强的体外和体内肿瘤起始特性,球体形成实验、自我更新实验、软琼脂实验和动物研究均证实了这一点。此外,我们的数据表明,Snail 和 Twist1,两种上皮-间充质转化(EMT)程序的已知转录因子,可能参与了 K562/A02 细胞获得肿瘤起始特性。因此,我们的研究表明,MDR K562/A02 细胞具有肿瘤起始特性,这可能是由于 Snail 和 Twist1 的表达升高。

相似文献

1
Multi-drug-resistant cells enriched from chronic myeloid leukemia cells by Doxorubicin possess tumor-initiating-cell properties.多柔比星诱导慢性髓系白血病细胞获得的多药耐药细胞具有肿瘤起始细胞特性。
J Pharmacol Sci. 2013;122(4):299-304. doi: 10.1254/jphs.13025fp. Epub 2013 Aug 1.
2
Coexpression of gene Oct4 and Nanog initiates stem cell characteristics in hepatocellular carcinoma and promotes epithelial-mesenchymal transition through activation of Stat3/Snail signaling.基因Oct4和Nanog的共表达启动了肝细胞癌中的干细胞特征,并通过激活Stat3/Snail信号通路促进上皮-间质转化。
J Hematol Oncol. 2015 Mar 11;8:23. doi: 10.1186/s13045-015-0119-3.
3
Influence of adriamycin on changes in Nanog, Oct-4, Sox2, ARID1 and Wnt5b expression in liver cancer stem cells.阿霉素对肝癌干细胞中Nanog、Oct-4、Sox2、ARID1和Wnt5b表达变化的影响。
World J Gastroenterol. 2014 Jun 14;20(22):6974-80. doi: 10.3748/wjg.v20.i22.6974.
4
JNK is required for maintaining the tumor-initiating cell-like properties of acquired chemoresistant human cancer cells.JNK是维持获得性化疗耐药的人类癌细胞的肿瘤起始细胞样特性所必需的。
Acta Pharmacol Sin. 2015 Sep;36(9):1099-106. doi: 10.1038/aps.2015.58. Epub 2015 Aug 3.
5
Snail1 induces epithelial-to-mesenchymal transition and tumor initiating stem cell characteristics.蜗牛 1 诱导上皮间质转化和肿瘤起始干细胞特征。
BMC Cancer. 2011 Sep 19;11:396. doi: 10.1186/1471-2407-11-396.
6
Silencing the OCT4-PG1 pseudogene reduces OCT-4 protein levels and changes characteristics of the multidrug resistance phenotype in chronic myeloid leukemia.沉默OCT4-PG1假基因可降低OCT-4蛋白水平,并改变慢性髓性白血病中多药耐药表型的特征。
Mol Biol Rep. 2019 Apr;46(2):1873-1884. doi: 10.1007/s11033-019-04639-4. Epub 2019 Feb 5.
7
Reversal effect of a macrocyclic bisbibenzyl plagiochin E on multidrug resistance in adriamycin-resistant K562/A02 cells.大环双苄基海兔素E对阿霉素耐药K562/A02细胞多药耐药性的逆转作用
Eur J Pharmacol. 2008 Apr 14;584(1):66-71. doi: 10.1016/j.ejphar.2008.01.039. Epub 2008 Feb 5.
8
Relationships between multidrug resistance (MDR) and stem cell markers in human chronic myeloid leukemia cell lines.人慢性髓性白血病细胞系中多药耐药(MDR)与干细胞标志物之间的关系。
Leuk Res. 2010 Jun;34(6):757-62. doi: 10.1016/j.leukres.2009.11.004. Epub 2009 Dec 6.
9
Ligustrazine derivate DLJ14 reduces multidrug resistance of K562/A02 cells by modulating GSTπ activity.川芎嗪衍生物 DLJ14 通过调节 GSTπ 活性降低 K562/A02 细胞的多药耐药性。
Toxicol In Vitro. 2011 Jun;25(4):937-43. doi: 10.1016/j.tiv.2011.03.002. Epub 2011 Mar 21.
10
CD133+ subpopulation of the HT1080 human fibrosarcoma cell line exhibits cancer stem-like characteristics.HT1080 人纤维肉瘤细胞系的 CD133+ 亚群表现出癌症干细胞样特征。
Oncol Rep. 2013 Aug;30(2):815-23. doi: 10.3892/or.2013.2486. Epub 2013 May 23.

引用本文的文献

1
Tyrosine Kinase Inhibitor Therapy Enhances Stem Cells Profile and May Contribute to Survival of Chronic Myeloid Leukemiastem Cells.酪氨酸激酶抑制剂疗法可增强干细胞特征,并可能有助于慢性髓性白血病干细胞的存活。
J Clin Med. 2025 Jan 10;14(2):392. doi: 10.3390/jcm14020392.
2
Cancer cell plasticity: from cellular, molecular, and genetic mechanisms to tumor heterogeneity and drug resistance.肿瘤细胞可塑性:从细胞、分子和遗传机制到肿瘤异质性和耐药性。
Cancer Metastasis Rev. 2024 Mar;43(1):197-228. doi: 10.1007/s10555-024-10172-z. Epub 2024 Feb 8.
3
Zebrafish drug screening identifies Erlotinib as an inhibitor of Wnt/β-catenin signaling and self-renewal in T-cell acute lymphoblastic leukemia.
斑马鱼药物筛选鉴定厄洛替尼为 T 细胞急性淋巴细胞白血病中 Wnt/β-连环蛋白信号和自我更新的抑制剂。
Biomed Pharmacother. 2024 Jan;170:116013. doi: 10.1016/j.biopha.2023.116013. Epub 2023 Dec 16.
4
Combination therapy with miR34a and doxorubicin synergistically inhibits Dox-resistant breast cancer progression down-regulation of Snail through suppressing Notch/NF-B and RAS/RAF/MEK/ERK signaling pathway.miR34a与阿霉素联合治疗通过抑制Notch/NF-κB和RAS/RAF/MEK/ERK信号通路协同抑制阿霉素耐药乳腺癌进展及Snail的下调。
Acta Pharm Sin B. 2021 Sep;11(9):2819-2834. doi: 10.1016/j.apsb.2021.06.003. Epub 2021 Jun 8.
5
Therapeutic potentials of resveratrol in combination with radiotherapy and chemotherapy during glioblastoma treatment: a mechanistic review.白藜芦醇在胶质母细胞瘤治疗中联合放疗和化疗的治疗潜力:一项机制综述
Cancer Cell Int. 2021 Jul 21;21(1):391. doi: 10.1186/s12935-021-02099-0.
6
Markers and Reporters to Reveal the Hierarchy in Heterogeneous Cancer Stem Cells.用于揭示异质性癌症干细胞层级结构的标志物与报告基因
Front Cell Dev Biol. 2021 Jun 3;9:668851. doi: 10.3389/fcell.2021.668851. eCollection 2021.
7
Recent Advances in Cancer Plasticity: Cellular Mechanisms, Surveillance Strategies, and Therapeutic Optimization.癌症可塑性的最新进展:细胞机制、监测策略与治疗优化
Front Oncol. 2020 Apr 22;10:569. doi: 10.3389/fonc.2020.00569. eCollection 2020.
8
Adaptive phenotypic modulations lead to therapy resistance in chronic myeloid leukemia cells.适应性表型调节导致慢性髓性白血病细胞的治疗耐药性。
PLoS One. 2020 Feb 27;15(2):e0229104. doi: 10.1371/journal.pone.0229104. eCollection 2020.
9
The Kraken Wakes: induced EMT as a driver of tumour aggression and poor outcome.《海妖觉醒:诱导 EMT 作为肿瘤侵袭和不良预后的驱动因素》。
Clin Exp Metastasis. 2018 Apr;35(4):285-308. doi: 10.1007/s10585-018-9906-x. Epub 2018 Jun 8.
10
Tendency of K562 Chronic Myeloid Leukemia Cells Towards Cell Reprogramming.K562慢性髓系白血病细胞的细胞重编程倾向
Turk J Haematol. 2018 Nov 13;35(4):260-264. doi: 10.4274/tjh.2018.0106. Epub 2018 May 21.